Business Wire

25,000 Health Facilities Across India Are Transforming Public Health Systems to Address Growing Critical Climate Issues

7.4.2023 12:00:00 EEST | Business Wire | Press release

Share

In 2021, WHO identified climate change as the biggest global health threat of the 21st century. While half of the world’s population continue to lack access to essential health services, according to a 2019 Health care climate footprint report, if the healthcare sector were a country, it would be the fifth largest greenhouse gas emitter on the planet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230407005011/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Aerial view of Khudei Khunou Health facility in North East India (Photo: Business Wire)

In a significant step towards transforming the public health infrastructure for improved sustainability, SELCO Foundation and IKEA Foundation, in partnership with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, have launched a groundbreaking initiative ‘Energy for Health’. The program recognises climate adaptation and mitigation at the center to all efforts to upgrade the public health facilities across the world.

Speaking about the significance of this program globally, Dr. Maria Neira, Assistant Director-General a.i., Division of Healthier Populations, and Director, Department of Environment, Climate Change and Health, at the World Health Organization said, “Reliable electricity in health-care facilities is essential to save lives and to provide quality health care. And yet, one billion people around the world are still served by health-care facilities without reliable electricity or with no electricity access at all. Decentralized renewable energies represent a key opportunity to accelerate electrification of health-care facilities, including in remote areas. I congratulate the Government of India and our partners from Selco Foundation and Ikea Foundation for this critical program, which will have a transformative impact on strengthening the health system”.

The first-of-a-kind initiative will bring solar energy solutions with efficient medical and electrical equipment to 25,000 healthcare facilities in 12 states by 2026. Across the 12 states under this program, there is a diversity in terms of topography, socio-economic vulnerabilities, disease burden and climate. This diversity across selected geographies will contribute to this programme serving as a showcase globally- innovating on approaches, models and processes relevant for similar contexts in other parts of the world.

Reflecting on India’s leadership in the effort, Dr. Harish Hande, CEO of SELCO Foundation said, “Affordable and equitable access to healthcare is a function of two aspects- one, resources required to deliver health care, and two, cost of accessing health care. Through this program, SELCO Foundation and IKEA Foundation, along with India’s Ministry of Health and Family Welfare (MOHFW) and various State Health Missions, will showcase at scale how sustainable energy can be used to make health services affordable at the doorstep of the poor.”

‘Energy for Health’ initiative brings with it positive impacts across the spectrum of stakeholders- for last mile communities in their access to timely healthcare; for health facility staff in ensuring a conducive work environment to provide quality services; for health sector in reducing energy and equipment-related costs as well as avoiding wastage of vaccines and other critical resources; reinforcing climate resilience building and carbon mitigation efforts while ensuring positive health outcomes for all citizens.

Mr. Per Heggenes, CEO of IKEA Foundation said, “‘At the IKEA Foundation, we strongly believe caring for the health of people and our planet must go hand-in-hand. This initiative will improve healthcare outcomes and reduce emissions, by providing reliable and renewable energy to thousands of clinics. Our hope is that the success of this programme can serve as a model for building effective and efficient health systems globally.’

Supported by IKEA Foundation, through this initiative, SELCO Foundation along with Government of India will create systems and processes that demonstrate ownership, management, and regular maintenance of the energy systems and appliances. Together, through the 25,000 public health facilities, technical knowledge and capacity, as well as guidelines and policies that enable health staff at different levels to plan for public health infrastructure in a sustainable manner will be improved. The program will also improve the local technical network for solar energy, which could potentially also have indirect impacts on local economies and boost adoption of solar energy across other sectors as well.

The initiative aims to reach over 170 million people across the 12 states and improve working conditions for over 160,000 front line health staff at these health facilities. Across the 25,000 public health facilities, this will add ~100MW of solar energy capacity in the country, and mitigate over 3 million tonnes of CO2e emissions over a 20 year period. These will directly contribute to India’s Net Zero targets, while also creating a paradigm shift on how health targets can be achieved for resource constrained communities across the world in an efficient manner.

About the partners:

SELCO Foundation:
Established in 2010, SELCO Foundation’s mission is to develop holistic solutions that use sustainable energy as a catalyst to address poverty alleviation alongside ensuring environmental sustainability. SELCO's interventions lead to the sustainable delivery of essential services such as healthcare, and enable improvements in livelihoods productivity and till date more than 7 million people have been impacted. The foundation does this by also developing enabling conditions, i.e the ecosystem for sustainable energy solutions to be locally developed, adopted, scaled and institutionalized through stakeholders including government agencies, financiers, local NGOs and enterprises.

For more information, visit www.selco foundation.org, and follow them on Twitter (@SELCOFoundation) and LinkedIn.

IKEA Foundation:
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families.

In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.

Learn more at: www.ikeafoundation.org or by following them on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lotika Mehta
lotika.mehta@ikeafoundation.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye